Compare PepsiCo, Inc. (PEP) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? PepsiCo, Inc. trades at $135.86 (market cap $184.26B), while Vertex Pharmaceuticals Incorporated trades at $474.2 (market cap $122.33B). The key difference: PepsiCo, Inc. is the larger of the two by market cap, and PepsiCo, Inc. pays a 4.39% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| PEP | VRTX | |
|---|---|---|
Market Cap | $184.26B | $122.33B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $529.59 |
52-Week Low | $134.98 | $366.54 |
Enterprise Value | $226.76B | $117.07B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $135.65, showing minimal daily movement with a slight 0.14% gain. The technical outlook is bearish per moving averages, while fundamentals reflect steady revenue near $94B and strong profitability with a 10.78% net margin. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, alongside ongoing North American recovery efforts ahead of Q1 2026 earnings.
The stock presents a mixed outlook: analyst consensus leans hold (64% of ratings) with a $158.79 price target suggesting upside, but risks include margin pressure from pricing strategies and volatile cash flows. Institutional activity shows mixed signals, with some firms increasing stakes while others reduce holdings, indicating cautious optimism amid competitive and consumer sentiment challenges.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
